Novel glycosaminoglycan biosynthetic inhibitors affect tumor-associated angiogenesis
- 19 November 2010
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 404 (1) , 86-89
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (GM075168)
This publication has 25 references indexed in Scilit:
- RGD-xyloside conjugates prime glycosaminoglycansGlycoconjugate Journal, 2010
- Click-xylosides mitigate glioma cell invasion in vitroMolecular BioSystems, 2010
- Differential effects of Heparitinase I and Heparitinase III on endothelial tube formation in vitroBiochemical and Biophysical Research Communications, 2010
- Chemical Tumor Biology of Heparan Sulfate ProteoglycansCurrent Chemical Biology, 2010
- Investigating the Elusive Mechanism of Glycosaminoglycan BiosynthesisJournal of Biological Chemistry, 2009
- Inhibition of Heparan Sulfate and Chondroitin Sulfate Proteoglycan BiosynthesisJournal of Biological Chemistry, 2008
- Chemical approaches to deciphering the glycosaminoglycan codeCurrent Opinion in Chemical Biology, 2005
- Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapiesJournal of Cellular Biochemistry, 2005
- CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix.Journal of Clinical Investigation, 1996
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971